AstraZeneca Turns To Celgene To Maximize Potential Of Its PD-L1 Inhibitor Program

AstraZeneca says partnering with Celgene on its PD-L1 asset MEDI4736 will maximize potential of its immuno-oncology pipeline in hematology, while a simultaneously agreed-upon alliance with Innate Pharma of France will further strengthen the pure pharma’s cancer-fighting franchise.